References
- 1Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md). 2016;64(1):73–84. DOI: 10.1097/HEP.0000000000000004
- 2Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020;158(7):1851–1864. DOI: 10.1053/j.gastro.2020.01.052
- 3Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metab. Clin Exp. 2016;65(8):1038–1048. DOI: 10.1016/j.metabol.2015.12.012
- 4Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589–600. DOI: 10.1016/j.jhep.2016.05.013
- 5Aakre KM, Saenger AK, Body R, et al. Analytical Considerations in Deriving 99th Percentile Upper Reference Limits for High-Sensitivity Cardiac Troponin Assays: Educational Recommendations from the IFCC Committee on Clinical Application of Cardiac Bio-Markers. Clin. Chem. 2022;68(8):1022–1030. DOI: 10.1093/clinchem/hvac092
- 6McEvoy JW, Tang O, Wang D, et al. Myocardial Injury Thresholds for 4 High-Sensitivity Troponin Assays in U.S. Adults. J. Am Coll Cardiol. 2023;81(20):2028–2039. DOI: 10.1016/j.jacc.2023.03.403
- 7Jia X, Sun W, Hoogeveen RC, et al. High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study. Circulation. 2019;139(23):2642–2653. DOI: 10.1161/circulationaha.118.038772
- 8McEvoy JW, Daya N, Tang O, et al. High-sensitivity troponins and mortality in the general population. Eur. Heart J. 2023;44(28):2595–2605. DOI: 10.1093/eurheartj/ehad328
- 9McEvoy JW, Wang D, Tang O, et al. Four high sensitivity troponin assays and mortality in US adults with cardiovascular disease: The national health and nutrition examination survey, 1999–2004. Am. J. Prev Cardiol. 2024;17:
100631 . DOI: 10.1016/j.ajpc.2023.100631 - 10Scheven L, de Jong PE, Hillege HL, et al. High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. Eur. Heart J. 2012;33(18):2272–2281. DOI: 10.1093/eurheartj/ehs163
- 11Cavender MA, White WB, Jarolim P, et al. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation. 2017;135(20):1911–1921. DOI: 10.1161/circulationaha.116.024632
- 12Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–913. DOI: 10.1016/s2468-1253(21)00308-3
- 13Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. DOI: 10.1186/1471-230x-6-33
- 14Seo IH, Lee HS, Lee YJ. Fatty liver index as a predictor for incident type 2 diabetes in community-dwelling adults: longitudinal findings over 12 years. Cardiovasc Diabetol. 2022;21(1):209. DOI: 10.1186/s12933-022-01642-1
- 15Loprinzi PD, Addoh O. Predictive Validity of the American College of Cardiology/American Heart Association Pooled Cohort Equations in Predicting All-Cause and Cardiovascular Disease-Specific Mortality in a National Prospective Cohort Study of Adults in the United States. Mayo Clin Proc. 2016;91(6):763–769. DOI: 10.1016/j.mayocp.2016.03.019
- 16Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69(5):547–558. DOI: 10.1093/gerona/glu010
- 17Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618–e651. DOI: 10.1161/cir.0000000000000617
- 18Bashar H, Kobo O, Curzen N, Mamas MA. Association of myocardial injury with adverse long-term survival among cancer patients. Eur J Prev Cardiol. 2024. DOI: 10.1093/eurjpc/zwae116
- 19Hu J, Du Y, Zhou Y, Wang H. High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease. Sci. Rep. 2024;14(1):
19541 . DOI: 10.1038/s41598-024-70645-7 - 20Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901–910. DOI: 10.1016/S2213-8587(14)70032-4
- 21Silveira Rossi JL, Barbalho SM, Reverete de Araujo R, Bechara MD, Sloan KP, Sloan LA. Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. Diabetes Metab Res Rev. 2022;38(3):
e3502 . DOI: 10.1002/dmrr.3502 - 22Xia W, Yang N, Li Y. Analysis of Risk Factors for Adverse Cardiovascular Events in Elderly Patients with Acute Myocardial Infarction and Non-Alcoholic Fatty Liver Disease (NAFLD). Med. Sci. Monit. 2020;26:
e922913 . DOI: 10.12659/MSM.922913 - 23VanWagner LB, Wilcox JE, Colangelo LA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology (Baltimore, Md). 2015;62(3):773–783. DOI: 10.1002/hep.27869
- 24Liu L, Cheng YT, Xu A, Cheung BMY. Association between high sensitivity cardiac troponin and mortality risk in the non-diabetic population: findings from the National Health and Nutrition Examination Survey. Cardiovasc. Diabetol.2023;22(1):296. DOI: 10.1186/s12933-023-02003-2
- 25Bisaccia G, Ricci F, Khanji MY, et al. Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Curr. Probl. Cardiol.2023;48(6):
101643 . DOI: 10.1016/j.cpcardiol.2023.101643 - 26Simon TG, Trejo MEP, McClelland R, et al. Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis. Int J Cardiol 2018;259:198–204. DOI: 10.1016/j.ijcard.2018.01.046
- 27Abd Alamir M, Goyfman M, Chaus A, et al. The Correlation of Dyslipidemia with the Extent of Coronary Artery Disease in the Multiethnic Study of Atherosclerosis. J. Lipids. 2018;2018:
5607349 . DOI: 10.1155/2018/5607349 - 28Martin SS, Blaha MJ, Blankstein R, et al. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation. 2014;129(1):77–86. DOI: 10.1161/circulationaha.113.003625
- 29Ma Y, Zhang L, Rong S, et al. Relation between gastric cancer and protein oxidation, DNA damage, and lipid peroxidation. Oxid. Med Cell Longev. 2013;2013:
543760 . DOI: 10.1155/2013/543760 - 30Neri M, Fineschi V, Di Paolo M, et al. Cardiac oxidative stress and inflammatory cytokines response after myocardial infarction. Curr. Vasc. Pharmacol. 2015;13(1):26–36. DOI: 10.2174/15701611113119990003
- 31Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(39):14205–14218. DOI: 10.3748/wjg.v20.i39.14205
- 32Vlachopoulos C, Manesis E, Baou K, et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. Am. J. Hypertens. 2010;23(11):1183–1189. DOI: 10.1038/ajh.2010.144
- 33Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–1350. DOI: 10.1056/nejmra0912063
- 34Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42(5):320–330. DOI: 10.1016/j.dld.2010.01.016
- 35Rosato V, Masarone M, Dallio M, Federico A, Aglitti A, Persico M. NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. Int J Environ Res Public Health. 2019;16(18). DOI: 10.3390/ijerph16183415
- 36Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65(2):425–443. DOI: 10.1016/j.jhep.2016.04.005
- 37Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313–3327. DOI: 10.1007/s00018-018-2860-6
- 38Bril F, Barb D, Portillo-Sanchez P, et al. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology (Baltimore, Md). 2017;65(4):1132–1144. DOI: 10.1002/hep.28985
- 39Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat. Rev. Gastroenterol. Hepatol. 2017;14(1):32–42. DOI: 10.1038/nrgastro.2016.147
- 40Stefan N, Häring HU. The role of hepatokines in metabolism. Nat. Rev. Endocrinol. 2013;9(3):144–152. DOI: 10.1038/nrendo.2012.258
- 41Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat. Rev. Endocrinol. 2017;13(9):509–520. DOI: 10.1038/nrendo.2017.56
- 42EASL-EASD-EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. DOI: 10.1016/j.jhep.2015.11.004
- 43Castellana M, Donghia R, Guerra V, et al. Performance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis. J. Clin. Med. 2021;10(9). DOI: 10.3390/jcm10091877